Want to see AEMD full AI Analyst Report?
AEMD Stock Chart & Stats
$2.40
>-$0.01(-0.43%)
At close: 4:00 PM EDT
$2.40
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$1.41 - $29.45
Previous CloseN/A
Volume26.32K
Average Volume (3M)3.28M
Market Cap
$8.26M
Enterprise Value-$2.98M
Total Cash (Recent Filing)$4.93M
Total Debt (Recent Filing)$367.61K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Nov 18, 2026EPS Estimate
-2.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.70
Shares Outstanding1,604,095
10 Day Avg. Volume57,663
30 Day Avg. Volume3,282,485
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.51
Price to Sales (P/S)0.00
P/FCF Ratio-1.05
Enterprise Value/Market Cap-0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.69
Enterprise Value/Ebitda0.45
Forecast
1Y Price Target
$1.50Price Target Upside-37.50% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-6.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressProgress into the final cohort demonstrates that the Hemopurifier program is advancing through planned early clinical evaluation. The absence of reported device-related serious events in the first final-cohort participant supports continued development, although efficacy remains unproven.
Platform Expansion And Scientific SupportExpansion across several disease areas increases the potential addressable use cases for the Hemopurifier beyond its initial oncology focus. Continued research and intellectual-property generation may strengthen the platform, create partnership opportunities, and support future clinical programs.
Cost Control And Operating RunwayLower operating expenses and post-quarter financing improve the company’s ability to continue clinical and research activities over the next several quarters. Management believes resources fund operations for at least 12 months, providing time to generate trial data and pursue strategic funding.
Bears Say
Minimal Revenue And Persistent LossesThe absence of meaningful revenue leaves Aethlon without demonstrated commercial operating leverage and makes future progress dependent on successful commercialization or additional financing. Persistent losses also indicate that the business is not yet self-sustaining and remains far from breakeven.
Preliminary Clinical EvidenceVery small cohorts provide limited statistical power and make the observed biomarker changes difficult to generalize across patients. Until larger studies and formal analyses demonstrate reproducible safety and efficacy, regulatory advancement and commercial adoption remain materially uncertain.
Funding And Treatment ConstraintsThe need for external funding beyond the current runway could constrain the pace and scale of clinical development and may create future financing or partnership dependence. Multi-hour treatment logistics and tolerability limits may also restrict practical trial design and eventual use.
Aethlon Medical News
AEMD FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was $1.41 and its highest was $29.45 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is $8.26M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Nov 18, 2026 which is in 29 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Aug 13, 2026. The company reported -$4.02 earnings per share for the quarter, missing the consensus estimate of -$3.925 by -$0.095.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Overvalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -2.7.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 1,604,095 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -$4.02 in its last earnings report, missing expectations of -$3.925. Following the earnings report the stock price went down -3.413%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in AEMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
AEMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.View all AEMD earnings summariesAEMD Stock 12 Month Forecast
Average Price Target
$1.50
▼(-37.50% Downside)
Technical Analysis
Ownership Overview
7.62% Insiders
0.43% Mutual Funds
0.90% Other Institutional Investors
91.05% Public Companies and
Individual Investors